Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
ICD-10 C77.1 is a billable code used to indicate a diagnosis of secondary and unspecified malignant neoplasm of intrathoracic lymph nodes.
C77.1 refers to secondary malignant neoplasms that have metastasized to the intrathoracic lymph nodes, which include lymph nodes located in the thoracic cavity. This condition typically arises from a primary malignancy elsewhere in the body, such as the lungs, breast, or gastrointestinal tract. The diagnosis of C77.1 indicates that the primary tumor is either unknown or has not been specified, which is common in cases where the patient presents with advanced disease. The presence of malignant cells in the intrathoracic lymph nodes can lead to various symptoms, including respiratory distress, cough, and chest pain. Staging of the disease is crucial for determining the extent of metastasis and guiding treatment options, which may include chemotherapy, radiation therapy, or palliative care. Palliative care considerations are particularly important for patients with advanced metastatic disease, focusing on symptom management and improving quality of life, as curative treatment may not be feasible.
Detailed history of the primary cancer, staging information, and treatment plans.
Patients presenting with symptoms of metastatic disease, such as weight loss, cough, or chest pain.
Accurate documentation of the primary site and staging is essential for treatment planning.
Pulmonary function tests, imaging studies, and symptom assessments.
Patients with respiratory symptoms and known history of cancer.
Documentation should include the impact of lymph node involvement on respiratory function.
Used when a biopsy is performed to confirm metastatic disease in the lymph nodes.
Documentation of the indication for biopsy and results.
Oncologists and pathologists must ensure accurate reporting of findings.
C77.1 indicates a secondary malignant neoplasm located in the intrathoracic lymph nodes, typically resulting from metastasis from a primary cancer site.
